Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
SciSparc (SPRC US)
Watchlist
83
Analysis
Health Care
•
Israel
SciSparc Ltd. provides pharmaceutical products. The Company develops cannabinoid technologies for treatment of central nervous system disorders. SciSparc serves customers worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Macroeconomics
•
06 Nov 2023 18:46
•
Broker
Monthly Report: November 2023: Outlook: To Fall Further (With Some Rebounds), With the Support at 1,350/1,320 Points and the Resistance at 1,400/1,420 Points
KTX expects the SET Index to fall further (with some rebounds), with the support at 1,350/1,320 points and the resistance at 1,400 1,420 points,...
Krungthai XSpring
Follow
89 Views
Share
bearish
•
Cross Asset Strategy
•
24 Oct 2023 16:37
•
Broker
Strategy Update: Fear > Greed: No Fund Inflows, No Upside (Cash Remains King)
Given the current pervasive downside risks to the SET, along with the looming potential for it to touch a new low for the year (with this year's...
Krungthai XSpring
Follow
89 Views
Share
bearish
•
Cross Asset Strategy
•
20 Oct 2023 11:02
•
Broker
Today's Dominant Ideas
Technically, the SET Index is expected to weaken, with the resistance at 1,432/1,440 points (10-day EMA) and the support at 1,413/1,400...
Krungthai XSpring
Follow
91 Views
Share
bearish
•
Macroeconomics
•
06 Oct 2023 18:36
•
Broker
Monthly Report: October 2023
KTX expects the SET Index to weaken, with the support at 1,445/1,425 points and the resistance at 1,505/1,535 points, This assessment is grounded...
Krungthai XSpring
Follow
91 Views
Share
bullish
•
Crude Oil
•
04 Oct 2023 10:29
•
Broker
Today's Dominant Ideas
Technically, the SET Index is expected to weaken, with the support at 1,433/1,422 points and the resistance at 1,455/1,460 points. Keep a close...
Krungthai XSpring
Follow
86 Views
Share
First
Previous
5
6
7
8
9
10
11
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x